BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12450432)

  • 1. Thymidylate synthase pharmacogenetics in colorectal cancer.
    Marsh S; McLeod HL
    Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
    Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ
    Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
    Marsh S; McKay JA; Cassidy J; McLeod HL
    Int J Oncol; 2001 Aug; 19(2):383-6. PubMed ID: 11445856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
    Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
    Brody JR; Hucl T; Gallmeier E; Winter JM; Kern SE; Murphy KM
    Cancer Res; 2006 Oct; 66(19):9369-73. PubMed ID: 17018589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer].
    Lee J; Jeong CK; Hong SP; Chong SY; Oh D; Hwang SG; Ahn DH; Kim S; Han JH; Kim NK
    Korean J Gastroenterol; 2005 Jul; 46(1):32-8. PubMed ID: 16030402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
    Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
    Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
    Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase pharmacogenetics.
    Marsh S
    Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
    de Bock CE; Garg MB; Scott N; Sakoff JA; Scorgie FE; Ackland SP; Lincz LF
    Pharmacogenomics J; 2011 Aug; 11(4):307-14. PubMed ID: 20531375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
    Park CM; Lee WY; Chun HK; Cho YB; Yun HR; Heo JS; Yun SH; Kim HC
    J Surg Oncol; 2010 Jan; 101(1):22-7. PubMed ID: 19798689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.